A Comparison of Three Extrusion Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems
The authors conducted an experiment to determine the type of extrusion that provides the best productivity and pellet quality. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

16. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

17. D. Djuric et al., Eur. J. Pharm. Biopharm. 71 (1), 155–160 (2009).

18. A. Debunne, C. Vervaet, and J.P. Remon, Eur. J. Pharm. Biopharm. 54 (3), 343–348 (2002).

19. A. Dukić et al., Eur. J. Pharm. Biopharm. 66 (1), 83–94 (2007).

20. H. Kanbe et al., Int. J. Pharm. 337 (1–2), 56–62 (2007).

21. A. Dukić-Ott et al., Eur. J. Pharm. Biopharm. 70 (1), 302–312 (2008).

22. K.E. Fielden, J.M. Newton, and R.C. Rowe, Int. J. Pharm. 97 (1–3), 79–92 (1993).

23. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

24. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

25. L. Hellén et al., J. Pharm. Tech. Int. 4 (9), 50–60 (1992).

26. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

27. C.C. Ku et al., Drug Dev. Ind. Pharm. 19 (13), 1505–1519 (1993).

28. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

29. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

30. K.A. Mehta et al., J. Control. Release 63 (1–2), 201–211 (2000).

31. S. Galland et al., Chem. Eng. Res. Des. 81 (9), 1237–1242 (2003).

32. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

33. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

34. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

35. C. Vervaet et al., Int. J. Pharm. 107 (1), 29–39 (1994).

36. C. Vervaet and J.P. Remon, Int. J. Pharm. 133 (1–2), 29–37 (1996).

37. R. Dietrich and R. Brausse, Pharm. Ind. 50 (10), 1179–1186 (1988).

38. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2) 205–214 (1997).

39. P.J. Harrison, J.M. Newton, and R.C. Rowe, J. Pharm. Pharmacol. 37 (10), 686–691 (1985).

40. J.F. Pinto, G. Buckton, and J.M. Newton, Int. J. Pharm. 83 (1–3), 187–196 (1992).

41. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

42. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

43. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here